Stem Cells & Heart Disease: Monkey Study Shows Promise
- In a collaborative effort, researchers from the University of Wisconsin-Madison and the Mayo Clinic are exploring stem cell therapy as a potential treatment for congenital heart defects.
- Heart disease remains the leading cause of death in the United States.
- Right ventricular dysfunction can cause chest discomfort, breathlessness, and heart weakening.
Groundbreaking research spotlights the potential of stem cell research to combat congenital heart defects. Scientists successfully integrated heart muscle cells derived from induced pluripotent stem cells into monkey hearts, mirroring conditions found in children. This innovative application offers hope for patients facing right ventricular dysfunction, a leading cause of chest discomfort adn heart weakening, often requiring transplants. This study, published in *Cell Transplantation*, utilized rhesus macaque monkeys. The goal is to improve heart function and perhaps prevent the need for heart transplants. News Directory 3 is following this development closely. The successful integration paves the way for human trials.Discover what’s next in this promising field.
Stem cell Therapy Shows Promise for Congenital Heart Defects
Updated June 29, 2025
In a collaborative effort, researchers from the University of Wisconsin-Madison and the Mayo Clinic are exploring stem cell therapy as a potential treatment for congenital heart defects. Their work, focusing on stem cell research, has shown promising results in primates.
Heart disease remains the leading cause of death in the United States. Congenital heart defects, present from birth, contribute substantially to this statistic.The team, led by Marina Emborg at UW-Madison and Timothy Nelson at the Mayo Clinic in Rochester, Minn., published their findings in Cell Transplantation. The study details how heart muscle cells, cultivated from induced pluripotent stem cells, successfully integrated into the hearts of monkeys experiencing pressure overload, a condition mirroring right ventricular dysfunction common in children with congenital heart defects.
Right ventricular dysfunction can cause chest discomfort, breathlessness, and heart weakening. While surgery offers temporary relief, many patients eventually require heart transplants. However, the scarcity of donor hearts, especially for young patients, presents a major hurdle. The stem cell therapy approach aims to bolster ventricular function and promote overall healing,potentially delaying or preventing the need for transplants,according to Jodi Scholz,led author and chair of Comparative Medicine at Mayo Clinic.
The team transplanted human induced pluripotent stem cells into rhesus macaque monkeys with surgically induced right ventricular pressure overload. The cells integrated into the heart’s muscular layer, the myocardium. While five of 16 animals experienced ventricular tachycardia (increased heart rate), these episodes resolved within 19 days. The animals’ health was closely monitored throughout.
Emborg emphasized the study’s focus on safety and successful tissue integration as a precursor to human trials. She noted that her team leveraged their experience with stem cells and cardiac evaluation in Parkinson’s disease to assess this new therapeutic approach.
The research marks the first successful use of stem cells in a nonhuman primate model of right ventricular pressure overload. Macaques have proven vital in advancing stem cell therapies for various conditions, including heart and kidney diseases.
Emborg said the successful integration and maturation of the cells into a compromised heart represents a promising step toward clinical applications for congenital heart defects.
What’s next
Further research will focus on refining the stem cell delivery methods and long-term monitoring of heart function in readiness for human clinical trials.